Clinical Research Studies
Click here for more information
Building on the momentum of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), this study focuses on participants with early mild cognitive impairment (eMCI)) to help researchers more fully understand Alzheimer’s disease progression in its earliest stages.
A Phase II clinical study of Ceregene's CERE-110, a gene therapy product designed to deliver nerve growth factor (NGF) to the brain for the treatment of Alzheimer's disease (AD) is currently underway.
Intravenous Immune Globulin (IVIg) has been approved and used successfully for over 20 years to treat a variety of autoimmune and immunodeficient diseases. Because it contains anti-amyloid antibodies IVIg is being investigated in a Phase III study as a treatment for Alzheimer's disease.
Researchers are participating in a new nationwide study that will test an experimental treatment to target the source of the disease. The experimental drug may block a critical pathway in AD that causes damage to the nerve cells in the brain. Participants will receive either the active study drug or placebo (inactive pill). All participants will be monitored carefully by a team of doctors and nurses at the research clinic throughout the study.
This study will evaluate three methods of performing home-based assessments in an Alzheimer's Disease (AD) prevention trial.
A Randomized Double-Blind Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer's Disease.
This study is a large five year (we began on Oct 1 2004) research project to study the rate of change of cognition, function, brain structure, function, and biomarkers in 200 elderly controls, 400 subjects with mild cognitive impairment, and 200 with Alzheimer's disease.
Primary Objective:To determine whether chronic valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in their illness.
A multicenter, double-blind, placebo-controlled therapeutic trial to determine whether natural huperzine A improves cognitive function in Alzheimer's Disease.
| Contact Us | Copyright ©2008 Regents of the University of California.